CD19-specific chimeric antigen receptor (CAR) T-cell therapy is a highly effective immunotherapy that is increasingly used for the treatment of children, adolescent and young adult (CAYA) patients with relapsed and/or refractory B-cell acute lymphoblastic leukemia (B-ALL)(1–5). The gene discussed is CD19; the disease is B-cell acute lymphoblastic leukemia.